Recently Enacted Law Offers New Exclusivity Incentives for Drugs Containing "Old" Antibiotics

Download IconDownload Print IconPrint

Recently Enacted Law Offers New Exclusivity Incentives for Drugs Containing "Old" Antibiotics

Client News
On October 8, 2008, President Bush signed into law S. 3560, the QI Program Supplemental Funding Act of 2008 (Public Law Number 110-379), which, among other things, amends the Federal Food, Drug, and Cosmetic Act (FDCA) to create new exclusivity opportunities for drug products containing "old" antibiotic ingredients. S. 3560 reverses certain provisions of the Food and Drug Administration Modernization Act of 1997 (FDAMA) that exempted products containing "old" antibiotics from the Hatch-Waxman provisions regarding marketing exclusivity and the patent listing and certification process. The new law accomplishes this in different ways for different categories of "old" antibiotics. For more, see our recent Email Alert.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel